Skip to main content

Month: December 2020

Cosmos Holdings Announces December 4th Virtual Bell Ringing to Open Trading on the OTCQX Best Market

CHICAGO, Dec. 04, 2020 (GLOBE NEWSWIRE) — Cosmos Holdings, Inc. (“the company”) (OTCQX: COSM), a vertically integrated international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, participated in a virtual “Open the Market” on the OTCQX® Best Market today at 9:30 a.m. EST. The virtual bell ringing can be viewed on the OTCQX Best Market social media channels:https://twitter.com/OTCMarkets/status/1334867689333026816?s=20https://www.linkedin.com/feed/update/urn:li:activity:6740633309879029761Cosmos Holdings, Inc. began trading on the OTCQX on November 25, 2020. The company was upgraded to OTCQX from the OTCQB® Venture Market. U.S. investors can find current financial disclosures and Real-Time Level 2...

Continue reading

Tauriga Sciences Inc. to Further Expand its Product Offerings With Dark Chocolate [20mg] CBD Infused Round Medallions

NEW YORK, NY, Dec. 04, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced the further expansion of its product offerings – with the development of dark chocolate [20mg] CBD Infused Round Medallions (“Medallions”).  Each dark chocolate medallion will be infused with 20mg CBD Isolate and will be sold exclusively on the Company’s E-Commerce website: www.taurigum.com. Additionally these dark chocolate medallions will be:  lab tested, kosher certified, cholesterol free, NON-GMO, THC Free, and Only 49 Calories...

Continue reading

Touax: share capital and voting rights at November 30, 2020

REGULATED INFORMATION                                                                                                                    Paris, 4 December 2020 5:45 PM YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATIONDisclosure of Share Capital and Voting RightsDisclosure of Share Capital and Voting Rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.Register name of the issuer: TOUAX SCA (Euronext Paris: TOUP)* excluding rights attached to shares held in treasury**************** TOUAX Group leases out tangible assets (freight railcars, river barges and containers) on a daily basis throughout the world, for its own account and on behalf of third party investors. With €1.2 billion under management, TOUAX is one of the European...

Continue reading

TOUAX: déclaration d’actions et de droits de vote au 30 novembre 2020

INFORMATION REGLEMENTEE                                                                                                             Paris, 4 décembre 2020 17:45VOTRE SOLUTION DE LOCATION AU SERVICE DES TRANSPORTS DURABLESDéclaration d’actions et de droits de voteDéclaration d’actions et de droits de vote en application de l’article L.233-8 II du Code de commerce et de l’article 223-16 du règlement général de l’AMF.Dénomination sociale de l’émetteur : TOUAX SCA (Euronext Paris : TOUP)* déduction faite des actions privées de droits de vote******* Le Groupe TOUAX loue des actifs tangibles (wagons de fret, barges fluviales et conteneurs) tous les jours dans le monde, pour son propre compte et pour le compte d’investisseurs. Avec près de 1,2 milliard d’euros sous gestion, TOUAX est un des leaders européens de la location de ce type de matériels.TOUAX...

Continue reading

AKWEL : Nombre total de droits de vote et d’actions au 30 novembre 2020

AKWELDéclaration relative au nombre total de droits de vote et d’actions prévues par les articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers      (1)   En raison d’auto détention par contrat d’animation Pièce jointe2020-11-30_AKWEL_DéclarationMensuelle_NbActionDroitsdeVote

Continue reading

Euronext announces volumes for November 2020

EURONEXT ANNOUNCES VOLUMES FOR NOVEMBER 2020Amsterdam, Brussels, Dublin, Lisbon, Oslo and Paris –  04 December 2020 – Euronext, the leading pan-European market infrastructure, today announced trading volumes for November 2020.Monthly and historical volume tables are available at this address:https://euronext.com/investor-relations#monthly-volumesCONTACTS –Media – mediateam@euronext.comAnalysts & investors – ir@euronext.com Aurélie Cohen                                                      +33 1 70 48 24 17;acohen@euronext.com Clément Kubiak                                                   +33 1 70 48 26 33; ckubiak@euronext.com About EuronextEuronext is the leading pan-European market infrastructure, connecting local economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated...

Continue reading

McPhy Energy : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 novembre 2020

Information relative au nombre total de droits de vote et d’actions composant le capital social établie conformément aux dispositions de l’article L. 233-8 II du code de commerce et de l’article 223-16 du Règlement général de l’AMFLa Motte-Fanjas, le 4 décembre 2020 – 17h45 CET – McPhy (Euronext Paris Compartiment C : MCPHY, FR0011742329) spécialiste des équipements de production et distribution d’hydrogène, annonce aujourd’hui la déclaration du nombre total des droits de vote et du nombre d’actions au 30 novembre 2020. Société déclarante Dénomination sociale : McPhy Energy S.A. Siège social : 1115 route de Saint-Thomas – 26190 La Motte-Fanjas Immatriculée sous le n° 502 205 917 R.C.S. Romans Euronext Paris Compartiment C (Code ISIN : FR0011742329 – MCPHY) Nombre d’actions formant le capital de la Société Nombre de droits de voteA...

Continue reading

Société Générale : Communication des exigences prudentielles de capital applicables au 1er janvier 2021

COMMUNICATION DES EXIGENCES PRUDENTIELLES DE CAPITAL APPLICABLES AU 1erJANVIER 2021Communiqué de presseParis, le 4 décembre 2020                              La Banque Centrale Européenne a notifié l’exigence de capital supplémentaire au titre du P2R  (Pillar 2 requirement) à partir du 1er janvier 2021. Cette dernière est inchangée et s’établit, pour Société Générale, à 1,75%.En tenant compte des différents coussins réglementaires ainsi que de la mise en œuvre anticipée de l’article 104A de la réglementation CRD5, les exigences minimales applicables à Société Générale sur base consolidée s’établissent respectivement à 9,03% pour le ratio CET1, 10,86% pour le ratio Tier 1 et 13,29% pour le ratio Total Capital.Avec un ratio CET1 du Groupe à 13,2%(1) au 30 septembre 2020, le Groupe bénéficie d’une marge confortable d’environ 420 points de...

Continue reading

Societe Generale: Disclosure of regulatory capital requirements as from 1 January 2021

DISCLOSURE OF REGULATORY CAPITAL REQUIREMENTS AS FROM 1 JANUARY 2021Press releaseParis, 4 December 2020The European Central Bank notified the level of additional requirement in respect of P2R (Pillar 2 Requirement) for Societe Generale, which will apply from 1 Janvier 2021. This level remains unchanged and will stand at 1.75% for Societe Generale.Taking into account the combined regulatory buffers as well as the early implementation of Article 104A of the CRD5 regulation, the minimum requirements applicable to Societe Generale on a consolidated basis are respectively 9.03% for the CET1 ratio, 10.86% for the Tier 1 ratio and 13.29% for the Total Capital ratio.With a CET1 ratio at 13.2% (1) as of 30 September 2020, the Group benefits from a comfortable buffer of almost 420 basis points above the threshold for triggering distribution limitations. (1) ...

Continue reading

Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)

– New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 –– Zygel™ Improves the Profound Sleep Disturbance Often Experienced by Developmental and Epileptic Encephalopathy (DEE) Patients Enrolled in the BELIEVE Trial –DEVON, Pa., Dec. 04, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters describing the efficacy, safety and quality of life results of the Phase 2 BELIEVE (Open Label Study to Assess the Safety and Efficacy of Zygel™ (ZYN002) Administered as a Transdermal Gel to Children and Adolescents with...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.